Table 2.

Inhibitors of cancer cell metabolism.

Name of Drug	Target Pathway	Lung Cancer Clinical Trail (Clinicaltrials.gov)
AZD3965	MCT1 (Lactate transport)	NCT01791595
CB-839 (Telaglenastat)	GLS (Glutaminolysis)	NCT02771626
CD-613 (Devimistat)	Mitochondrial PDH/KGDH	N/A
IM156	Mitochondrial ETC Complex 1	NCT03272256
L-γ-Glutamyl-p-nitroanilide (GPNA)	Glutamine transport	N/A
Metformin	Mitochondrial ETC Complex 1	NCT02285855 NCT01997775
PFK-15	PFKFB3 (Glycolysis)	N/A
PFK-158	PFKFB3 (Glycolysis)	NCT02044861
Phenformin	Mitochondrial ETC Complex 1	NCT03026517
SR13800	MCT1 (Lactate transport)	N/A
WZB 117	GLUT1 (Glycolysis)	N/A
2– Deoxy-d-Glucose (2DG)	HK2 (Glycolysis)	NCT00096707 NCT00633087

Many metabolic inhibitors have been utilized in clinical trials, however few have led to FDA approval. This table provides a list of the inhibitors described in Figure 3 and any associated clinical trials that have accepted lung cancer patients.

N/A, not applicable.